Quantifying cell-derived changes in collagen synthesis, alignment, and mechanics in a 3D connective tissue model
Described herein are in vitro quantitative methods directed to 3D extracellular matrix (ECM) organization and mechanics. The methods do not require application of an external force, anchorage, or a scaffolding material in order to culture ECM tissue constructs, and the methods enable quantitative measurements without crosstalk noise from variables attributable to external forces, anchorage, and scaffolding material.
1. An in vitro quantitative method for proportionally quantifying changes in a 3D extracellular matrix (ECM) mechanics, alignment and organization due to a presence, an amount, a time of contact, a concentration or an absence of a test condition during a synthesis of the ECM, the method comprising the steps of:
(1) obtaining a non-adhesive cell culture well including a non-adhesive peg disposed in the center of the well configured to develop a cellular alignment around the peg during a culture of anchorage-dependent cells and self-assembling cells, whereby the anchorage-dependent and self-assembling cells are operative to grow around the peg and self-aggregate and self-assemble using only one or more cell-derived forces;
(2) seeding the culture well with a culture medium and the anchorage-dependent cells and the self-assembling cells, wherein the cells are configured to synthesize ECM components and the ECM during a cultivation;
(3) cultivating the cells, whereby the cells grow and adhere to one another without an application of an external force, an anchorage force/material and a scaffolding material, but the cells do not adhere to the well and do not adhere to the peg; whereby the cells exert cytoskeleton-mediated tension and cell-driven self-assembly to form a 3D ring-shaped geometry of tissue ECM around the peg; wherein the ring-shaped geometry of ECM includes the tension, the cell-driven self-assembly, the cellular alignment around the peg from steps (1)-(3), and mechanics and organization that are all free of an effect from an external force, anchorage force/material and a scaffolding material thereby providing the ECM with a no cell-to-scaffold biophysical crosstalk and a no cell-to-external force biophysical crosstalk;
(4) measuring one or more properties of the tissue ECM to obtain a proportional signal for each of the one or more properties;
(5) providing a test condition and repeating steps (1)-(4) with a contacting of the cells with the test condition by contacting the tissue ECM and/or cells with an agent, a force, or a factor; whereby the presence, amount, time of contact, concentration or absence of the test condition either does or does not cause a proportional and quantitative, un-predicted, observable and measurable change in the one or more properties of the ECM and whereby the measuring in step (4) measures the proportional signal that is a quantitative response to the presence, amount, time of contact, concentration or absence that causes a proportional change in the one or more properties, then comparing the proportional signal before the contacting and the proportional signal after the contacting;
wherein the method is configured to provide tissue ECM that does not cause a noise value and/or a crosstalk value in the signal of the measuring of the change from the test condition because of an absence of a scaffolding material, and anchorage force/material and an externally applied force during the execution of steps (1), (2), (3), (4) and the method is configured to provide an absence of a noise value including a no cell-to-scaffold biophysical crosstalk signal and a no cell-to-external force biophysical crosstalk signal; and wherein the absence of the noise value and/or the crosstalk values provides and enables a quantitative method that is proportionally responsive to a presence of test condition, an absence of test condition, a time of contact of test condition applied and/or a difference in amount/magnitude of the test condition.
2. The method of claim 1 , wherein the cultivating is performed in an absence of an exogenously added scaffolding material and in absence of a material that is adhesive for cells or operative as an anchoring material.
3. The method of claim 1 , wherein the cultivating is performed without an application of an externally applied force, and wherein the anchorage-dependent and self-assembling cells provide a self-force by self-assembling around the peg.
4. The method of claim 1 , further comprising wherein the method is operative to effect a quantitative change in one or more properties of the tissue ECM and/or the cells due to a presence, absence, time of contact, and/or a difference in amount/magnitude of one or more test compounds and/or biological agents; wherein the quantitative change is proportional to the one or more test compounds and/or biological agents; and wherein the quantitative change is further effected by an additional execution of steps (6) and (7) below:
(6) recording the one or more properties of the tissue ECM and/or the cells without contacting with one or more test compounds and/or biological agents and then contacting the tissue ECM and/or the cells with the one or more test compounds and/or biological agents; and
(7) waiting for a period of time then repeating the recording in step (6) and comparing the one or more properties of the tissue ECM and/or the cells before the contacting in step (6) to the one or more properties of the tissue ECM and/or the cells after the waiting for the period of time;
whereby the waiting for the period of time and comparing and/or comparison in step (7) is configured to/operative to effect a quantitative change in one or more properties of the tissue ECM and/or the cells and to provide a quantitative measurement by the comparing and/or comparison.
5. The method of claim 1 , wherein the cellular alignment is only and solely directed by one or more cell-derived forces, a cell-mediated tension, and a circumferential cellular alignment around the peg.
6. The method of claim 1 , further comprising the step of:
(a) removing the tissue ECM and/or the cells from the culture well.
7. The method of claim 1 , wherein the measuring comprises an aid of an instrumentation; a measurement of structure-function relationships; a measurement of geometry of ECM, a measurement of a size of ECM, an alignment of ECM, a spatial distribution of cells and/or of ECM; a measurement of an instantaneous relaxation of ECM after removal from the culture well; an ECM or collagen crimping behavior; a quantification using a minimum cross-sectional area or a mean cross-sectional area; a measurement of ECM or collagen content per cell; a measurement of histology, a multiphoton second-harmonic generation measurement, an electron microscopy, and/or serial block-face scanning electron microscopy; a measurement of mechanical testing, tensile strength, maximum tangent modulus, stiffness, failure strain, thickness measurement (x-y), and/or length measurement (z); a measurement of circumferentially-aligned fibrillar ECM or collagen; video, imaging, and/or microscopy; pepsin-acid soluble collagen fraction; a measurement of tissue homeostasis and/or dysregulation; hematoxylin and eosin staining, or Masson's trichrome staining; measurement of a degree of crosslinking; measurement including a simulation of motion; measurement of cell-derived changes, changes in synthesis, organization, alignment, and/or mechanics of the ECM; fatigue testing; measurement of one or more secreted soluble factors in the culture medium; measurement of proteomics; or a measurement of genomics.
8. The method of claim 1 , wherein the test condition comprises; an aging condition, a test of a mechano-transduction pathway, a genotype and/or phenotype difference, an addition of nucleic acids or amino acids, a presence of an additional cell type, a presence of a virus and/or prion, a difference in medium composition, a difference in concentration of one or more factors, growth factors, drugs affecting cell-mediated synthesis, one or more biological perturbations, fetal bovine serum, ROCK-Inhibitor, TGF-β1 inhibitor, an interleukin, a nutrient formulation, electromagnetic radiation, particle bombardment, gravitational force, oxygen and/or gas level, a cytokine, temperature, mechanical conditioning, vibration or motion, pressure or vacuum, time, differences in cell origin(s), gene mutations affecting ECM synthesis, organization, or a test of mechanics relevant to connective tissue diseases.
9. The method of claim 1 , further comprising the method is a drug dose response method, wherein the one or more properties of the tissue ECM (experimental) are compared to a tissue ECM cultivated without a presence of the test condition, a native tissue ECM, or a tissue ECM cultivated in vivo (control); and wherein the comparison is operative to provide a drug dose (factor) response including the control and the experimental with a proportional and quantitative signal that is proportional the drug dose response, and wherein the method is executed with at least two different concentrations or doses of the drug or test condition.
10. The method of claim 1 , wherein the culture medium is serum-free.
11. The method of claim 1 , wherein the well and/or the peg comprises a hydrogel.
12. The method of claim 1 , wherein the well and/or the peg comprises a non-adhesive agarose.
13. The method of claim 1 , further comprising a proviso that wherein the measuring in step (4) does not contain a noise value and/or a crosstalk value in a signal of the measuring in step (4) because an absence of a scaffolding material and/or an externally applied force during the execution of steps (1), (2), (3), and (4) is configured to provide no cell-scaffold biophysical crosstalk and no cell-external force biophysical crosstalk which would both be present if the method were to be executed with an external force, anchorage force/material or a scaffolding material.
14. The method of claim 1 , further comprising wherein the method is configured as a method of investigating a disease or condition due to the further execution of steps (6) and (7) below:
(6) recording the one or more properties of the tissue ECM and/or the cells without contacting with one or more growth factors, tissue dysregulation factors and/or biological agents, and then contacting the tissue ECM and/or the cells with the one or more growth factors, tissue dysregulation factor and/or biological agents;
(7) waiting for a period of time then repeating the recording in step (6) and comparing the one or more properties of the tissue ECM and/or the cells before the contacting in step (6) to the one or more properties of the tissue ECM and/or the cells after the contacting in step (6) after the waiting for the period of time;
whereby the comparing and/or comparison in step (7), after the period of time, is configured to/operative to effect a quantitative change in one or more properties of the tissue ECM and/or the cells and to provide a quantitative measurement by the comparing and/or comparison; and wherein the wherein the quantitative measurement is configured to provide an investigating and/or diagnosing of a disease or condition.
15. The method of claim 1 , wherein the method comprises an investigating or a diagnosing of; fibrosis, Marfan Syndrome, Loeys-Dietz syndrome, a deregulated TGF-β signaling, cancer, changes in tissue mechanics, tissue mechanical failure, Ehlers-Danlos syndrome, or Osteogenesis Imperfecta.
16. A quantitative screening method for therapeutic agents or a method for evaluating the efficacy or toxicity of a therapeutic agent candidate substance acting on cells or tissues comprising the method of claim 1 ; further comprising wherein the method is provided by an execution of steps (6) and (7) below:
(6) recording the one or more properties of the tissue ECM and/or the cells without contacting with one or more therapeutic agents and then contacting the tissue ECM and/or the cells with the one or more therapeutic agents; and
(7) waiting for a period of time then repeating the recording of step (6) and comparing the one or more properties of the tissue ECM and/or the cells before the contacting in step (6) to the one or more properties of the tissue ECM and/or the cells after the contacting in step (6);
whereby the comparing and/or comparison in step (6) after the waiting for the period of time is configured to/operative to effect a quantitative change in one or more properties of the tissue ECM and/or the cells and to provide a quantitative measurement by the comparing and/or comparison.
17. The method of claim 1 , further comprising the method is configured as a method of culturing cells, ECM, or tissues, including the method of claim 1 , with a proviso that the method can be performed with or without a test condition: wherein the method of culturing cells, ECM, or tissues is configured to provide cells, ECM, or tissues that do not cause a noise value and/or a crosstalk value; and wherein the method further comprising removing the cells, ECM or tissues from the cell culture well and providing the cells, ECM or tissues for a test that is executed at a later time.
18. The method of claim 1 , wherein the cells comprise cells from: neonate male foreskin, dermis, tendon, lung, umbilical cords, cartilage, urethra, corneal stroma, oral mucosa, intestine, bone marrow, placenta, amnion, muscle, adipose, bone,
human dermal fibroblasts, human umbilical cord perivascular cells, fibroblasts, stromal cells, mesenchymal stem cells, transfected cells, recombinant cells, genetically engineered cells, immune cells, macrophages, or eosinophils.
19. The method of claim 1 , wherein the culture medium comprises spheroids including cells or monodispersed cells.